Search Videos and More
News
Advancing New Treatments for Uncommon Cancer Subtypes
The biology of rare cancers is poorly understood in part because the tumors are uncommon, which makes them challenging to study. Clinical trials examining rare cancers are difficult.
News
Study Finds Breast Cancers with Low Levels of HER2 Protein Are Not a Distinct Subtype of the Disease
When researchers discovered that breast cancers with lower levels of HER2 often respond to a trastuzumab-and-chemotherapy drug conjugate, they wondered whether such tumors represent a distinct subtype of breast cancer, with its own unique behavior and prognosis.
Document
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on August 4, September 3, October 8, 2021, and June 24, 2022 to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.
Symposium
Breast Cancer Treatment Guidelines
Following the FDA approval of certain treatments for breast cancer, the faculty in the Breast Oncology Program at Dana-Farber Brigham Cancer Center met to formalize guidelines for how to best utilize the new medications.
News
Dana-Farber’s Judy Garber Is Recipient Of Brinker Award For Scientific Distinction
This year’s Brinker Award for Scientific Distinction in Clinical Research is being presented today to Judy Garber, M.D., M.P.H., Chief of the Division of Cancer Genetics and Prevention at Dana Farber Cancer Institute.
News
Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Some Patients
Uterine cancers that developed in patients treated with tamoxifen had fewer PI3K pathway mutations and may have instead been driven by tamoxifen-induced PI3K pathway activation, according to results presented at the 2021 San Antonio Breast Cancer Symposium.
News
Dana-Farber Brigham Cancer Center Launches New Program for Women with Earliest Form of Breast Cancer
Dana-Farber Brigham Cancer Center is launching a new program designed to address the unique needs of women diagnosed with the earliest form of breast cancer. Nearly 60,000 women in the United States this year will be diagnosed with Ductal carcinoma in situ (DCIS), a type of breast cancer in which cancerous cells grow but are confined within the milk duct of the breast. The new program will offer DCIS patients outstanding clinical care delivered by Dana-Farber Brigham Cancer Center experts and will be the only such program in Greater Boston offering patients access to clinical trials specific to DCIS.
News
New Study Shows Young Women With Breast Cancer Who Opt for Mastectomies Report Lower Quality of Life
Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber Brigham Cancer Center.
Video
Breast Cancer Research at ESMO
Dana-Farber's Sara Tolaney, MD, MPH, provides insight on DESTINY-Breast09 trial highlighted at ESMO 2021.
News
Dosing Strategies Help Personalize Care in HER2+ Breast Cancer
Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.
Video
Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials
Sara Tolaney, MD, MPH discusses updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0.
News
Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch
An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows.